Assignee
DR FALK PHARMA GMBH
DE·14 granted patents·6 pending applications·21 citations·filing 2014–2025
Top patents by PatentIndex Score
20 records- 0190US9867780B2Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagusDR FALK PHARMA GMBH·Filed 2014·Granted Jan 16, 2018·17 cites·12 claims
- 0283US10695291B2Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagusDR FALK PHARMA GMBH·Filed 2019·Granted Jun 30, 2020·1 cites·9 claims
- 0382US10369100B2Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagusDR FALK PHARMA GMBH·Filed 2017·Granted Aug 6, 2019·3 cites·23 claims
- 0480US2026053818A1Pharmaceutical formulation for the treatment of inflammatory changes to the rectumDR FALK PHARMA GMBH·Filed 2025·Application pending·0 cites
- 0579US12472191B2Pharmaceutical formulation for the treatment of inflammatory changes to the rectumDR FALK PHARMA GMBH·Filed 2023·Granted Nov 18, 2025·0 cites·17 claims
- 0677US12459906B23-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitorsDR FALK PHARMA GMBH·Filed 2022·Granted Nov 4, 2025·0 cites·18 claims
- 0768US11382860B2Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagusDR FALK PHARMA GMBH·Filed 2020·Granted Jul 12, 2022·0 cites·21 claims
- 0866US11738032B2Pharmaceutical formulation for the treatment of inflammatory changes to the rectumDR FALK PHARMA GMBH·Filed 2020·Granted Aug 29, 2023·0 cites·18 claims
- 0961US12064509B2Enema for rectal applicationDR FALK PHARMA GMBH·Filed 2022·Granted Aug 20, 2024·0 cites·8 claims
- 1059US11464733B2Enema for rectal applicationDR FALK PHARMA GMBH·Filed 2017·Granted Oct 11, 2022·0 cites·2 claims
- 1158US2024238194A1Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitisDR FALK PHARMA GMBH·Filed 2022·Application pending·0 cites
- 1255US2025041228A1Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosisDR FALK PHARMA GMBH·Filed 2022·Application pending·0 cites
- 1352US10905699B2Pharmaceutical formulation for the treatment of inflammatory changes to the rectumDR FALK PHARMA GMBH·Filed 2016·Granted Feb 2, 2021·0 cites·8 claims
- 1451US10000526B2Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle sizeDR FALK PHARMA GMBH·Filed 2016·Granted Jun 19, 2018·0 cites·18 claims
- 1549US2023165845A1Systemic formulation of a pyridinone derivate for tg2-related diseasesDR FALK PHARMA GMBH·Filed 2021·Application pending·0 cites
- 1648US2023165844A1Systemic formulation of a pyridinone derivate for coeliac diseaseDR FALK PHARMA GMBH·Filed 2021·Application pending·0 cites
- 1746US11173121B2Pellets having a multi-layer structure for delayed release of the active substance in the distal colonDR FALK PHARMA GMBH·Filed 2019·Granted Nov 16, 2021·0 cites·15 claims
- 1844US11850252B2Use of nor-ursodeoxycholic acid for reducing liver fatDR FALK PHARMA GMBH·Filed 2018·Granted Dec 26, 2023·0 cites·16 claims
- 1936US11135159B2Optimized high-dose mesalazine-containing tabletDR FALK PHARMA GMBH·Filed 2016·Granted Oct 5, 2021·0 cites·14 claims
- 2030US2018271786A1Enema for rectal applicationDR FALK PHARMA GMBH·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when DR FALK PHARMA GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →